Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2BTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3MPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PPARGSLC6A2SLC6A3SLC6A4SMOTYK2pol
The experimentally established mechanism targets of Icopezil. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Icopezil SCHEMBL3339253 | 1.00 | ACHE (1.00) | ACHEBCHE | |
| Icopezil SCHEMBL9276204 | 0.96 | ACHE (0.93) | ACHEBCHE | |
| Icopezil SCHEMBL9276199 | 0.96 | ACHE (0.93) | ACHEBCHE | |
| Icopezil SCHEMBL194482 | 0.94 | ACHE (1.00) | ACHEBCHE | |
| SCHEMBL4512593 | 0.91 | ACHE (1.00) | ACHEBCHE | |
| SCHEMBL2402320 | 0.89 | ACHE (0.90) | ACHEBCHE | |
| Maleic Acid SCHEMBL3926936 | 0.87 | ACHE (0.77) | ACHEBCHE | |
| SCHEMBL220485 | 0.87 | ACHE (1.00) | ACHEBCHE | |
| SCHEMBL2405514 | 0.86 | ACHE (0.84) | ACHEBCHE | |
| SCHEMBL2403486 | 0.85 | ACHE (0.82) | ACHEBCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4509120-A2 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | Amylyx Pharmaceuticals Inc. (US) | 2025-02-19 | — | — | EP | claimed |
| US-12186330-B2 | Compositions for improving cell viability and methods of use thereof | Amylyx Pharmaceuticals Inc. (US) | 2025-01-07 | — | — | US | claimed |
| US-20220160733-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | Amylyx Pharmaceuticals Inc. | 2022-05-26 | — | — | US | claimed |
| WO-2011151359-A1 | COMBINED TREATMENT WITH A CHOLINESTERASE INHIBITOR AND A THIADIAZOLIDINEDIONE DERIVATIVE | NOSCIRA, S.A. (ES) | 2011-12-08 | — | — | WO | claimed |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | claimed |
| CN-101500611-A | Combination of a cholinesterase inhibitor and a compound with 5-HT6 receptor affinity | ESTEVE LABOR DR (ES) | 2009-08-05 | — | — | CN | claimed |
| EP-2040755-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-04-01 | — | — | EP | claimed |
| US-20080009467-A1 | COMBINATIONS OF MEDIUM CHAIN TRIGLYCERIDES AND THERAPEUTIC AGENTS FOR THE TREATMENT AND PREVENTION OF ALZHEIMERS DISEASE AND OTHER DISEASES RESULTING FROM REDUCED NEURONAL METABOLISM | ACCERA, INC. (US) | 2008-01-10 | — | — | US | claimed |
| WO-2007147883-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-12-27 | — | — | WO | claimed |
| US-12637450-B2 | Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways | GLOBAL CANCER TECHNOLOGY INC. (US) | 2026-05-26 | — | — | US | disclosed |
| US-20250275985-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | AMYLYX PHARMACEUTICALS, INC. | 2025-09-04 | — | — | US | disclosed |
| EP-3774783-B1 | TRI-SUBSTITUTED ARYL AND HETEROARYL DERIVATIVES AS MODULATORS OF PI3-KINASE AND AUTOPHAGY PATHWAYS | NEUROPORE THERAPIES INC (US) | 2025-06-04 | — | — | EP | disclosed |
| EP-4509120-A2 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | Amylyx Pharmaceuticals Inc. (US) | 2025-02-19 | — | — | EP | disclosed |
| US-12186330-B2 | Compositions for improving cell viability and methods of use thereof | Amylyx Pharmaceuticals Inc. (US) | 2025-01-07 | — | — | US | disclosed |
| EP-1086706-A1 | STABILIZED COMPOSITIONS CONTAINING NOOTROPIC DRUGS | Eisai Co., Ltd. (JP) | 2001-03-28 | — | — | EP | disclosed |
| US-6193993-B1 | Suppository containing an antidementia medicament | EISAI CO., LTD. (JP) | 2001-02-27 | — | — | US | disclosed |
| EP-1048302-A2 | Radiotracers for in vivo study of acetylcholinesterase and Alzheimer's disease | Pfizer Products Inc. (US) | 2000-11-02 | — | — | EP | disclosed |
| EP-0947193-A2 | Percutaneously applicable preparation and suppository containing an antidementia medicament | Eisai Co., Ltd. (JP) | 1999-10-06 | — | — | EP | disclosed |
| US-5538984-A | Methods of using piperidyl-benzisoxazole and benisothiazole derivatives as cholinesterase inhibitors | PFIZER INC. (US) | 1996-07-23 | — | — | US | disclosed |
| WO-1992017475-A1 | HETEROCYCLIC-CYCLIC AMINE DERIVATIVES | PFIZER INC. (US) | 1992-10-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220160733-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | HSPA9, CYP27A1, TUFM | ACHE 3040/4885BCHE 531/4885 |
| US-20250275985-A1 | COMPOSITIONS FOR IMPROVING CELL VIABILITY AND METHODS OF USE THEREOF | HSPA9, CYP27A1, TUFM | ACHE 3040/4885BCHE 531/4885 |
| US-12637450-B2 | Tri-substituted aryl and heteroaryl derivatives as modulators of PI3-kinase and autophagy pathways | PIK3R4, PIK3R1, ATG7 | ACHE 4865/4885BCHE 4568/4885 |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, AANAT, ACHE | ACHE 3/4885BCHE 14/4885 |
| US-20080009467-A1 | COMBINATIONS OF MEDIUM CHAIN TRIGLYCERIDES AND THERAPEUTIC AGENTS FOR THE TREATMENT AND PREVENTION OF ALZHEIMERS DISEASE AND OTHER DISEASES RESULTING FROM REDUCED NEURONAL METABOLISM | ACHE, CHAT, BACE1 | ACHE 1/4885BCHE 34/4885 |
| US-12186330-B2 | Compositions for improving cell viability and methods of use thereof | HSPA9, CYP27A1, TUFM | ACHE 3040/4885BCHE 531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.